• banner_1.jpg
  • banner_2.jpg
  • banner_3.jpg
  • banner_4.jpg
  • banner_5.jpg
  • banner_6.jpg
  • innovation_group_photo.jpg



Prof. Ian H Frazer FAA FRCP(Ed), FRCPA, Chair and Non-executive Director

Professor Ian Frazer is a clinician and pathologist, trained in immunology at Edinburgh University and the Walter and Eliza Hall Institute in Melbourne. His accomplishments include a 15-year track record of world-class research in viral immunology and vaccine development. He has a portfolio of eight completed patents. He has collaborated over 13 years with CSL Ltd and Merck & Co to commercialize a cervical cancer prophylactic vaccine, and to develop therapeutic vaccines for HPV infection. He was the first to identify the HPV L1 protein as a vaccine candidate. In 1999 he won an Australian Biotechnology Award for successful collaborative research leading to product commercialization. In 2004 he was inducted into the prestigious Australian Academy of Sciences in recognition of the significant contribution he has made to biomedical science.

Lee Rodne BA MBA, Non-executive Director

Lee Rodne has over 15 years of leadership experience in technology, healthcare, medical devices, and mining & renewable energy sectors in North America, UK and Australia. He is a results-driven leader with expertise in business development, strategic management, M&A and commercialising new technology-based initiatives. Lee has been in Executive leadership roles in both Public and Private enterprises and is the current Managing Director of Allied Healthcare Group Ltd. Lee holds an MBA from the University St. Thomas, Minnesota and a B.A. degree in Business Management from St. John's University, Minnesota.

Julian Chick PhD, Non-executive Director

Julian Chick, COO Allied Healthcare Group Ltd., is an experienced corporate executive with 10 years experience in senior management with several roles as CEO (including Avexa Ltd), Head of Business Development at Amrad, plus running early and late stage R&D projects, particularly in the area of infectious diseases. In the past 6 years Julian has raised over $170M for R&D. In addition, he had five years experience as an investment adviser and financial consultant with Prudential-Bache Securities, BNP Paribas and Salomon Smith Barney. Julian also was the principal analyst with Foursight Associates reviewing healthcare and biotechnology investment opportunities for private equity investors and venture capitalists. He has a PhD in Muscle Physiology from La Trobe University.

Peter Turvey BA LLB, MAICD, Non-executive Director

Peter Turvey worked at CSL for 19 years, initially appointed as the first corporate counsel and was then appointed Company Secretary and Group General Counsel at CSL in 1998. During his time at CSL, Peter played a major role as part of the executive team that built CSL into the international company it is today. He was also responsible for the management and licensing of CSL's intellectual property portfolio and overseeing risk management for the Group. Peter was involved in many licensing deals, most notably the HPV vaccine Gardasil® license to Merck & Co., the licensing of Iscomatrix® adjuvant platform technology to several of the world's leading vaccine manufacturers, and establishment of the P.gingivalis vaccine technology collaboration between the CRC for Oral Health and Sanofi Pasteur. Peter is currently a Principal at Foursight Associates and a Non-Executive Director on the Board of listed biotechnology companies Allied Healthcare Group Ltd and Starpharma Holding Ltd as well as Non-Executive Director of Agriculture Victoria Services Pty Ltd, a Victorian Government owned entity formed to commercialise the intellectual property developed out of the Department of Environment and Primary Industry.

Dean Moss BSc MPhil PhD, GAICD, Non-executive Director

Dean Moss is CEO of UniQuest and serves as a UniQuest-appointed member of the Board of Directors. Dean has over 25 years’ experience in science, academia, business, management and commercialisation in Australia, USA and the UK.  He has been managing director or senior business development executive of several health and biotech companies worldwide, including Agen Biomedical, Launch Diagnostics, AMRAD ICT, AMRAD Biotech, and United Drug. He established his own start-up business in the UK, York Medical Technologies.  Dean is a board member of several Australian companies and a member of the investment committee of the pre-seed venture funds Uniseed, the Medical Research Commercialisation Fund and the New Zealand Government’s KiwiNet.  He has contributed to raising over $50m in venture capital investment.

Stephen Denaro B Bus QUT; Grad Dip App Corporate Governance, Company Secretary

Stephen is a qualified chartered accountant with previous public company CFO and Secretary experience with biotech and software companies. He has ASX listing experience, and has strong relevant corporate equity and debt funding management skills. Stephen assists with financial and governance reporting to the Board. 


Neil Finlayson BSc (Hons) BCom, Chief Executive Officer

Neil Finlayson has extensive experience in banking and finance, JVs, partnering and licensing, and in company formations. Neil was formerly Business Development Director of Bio Innovation SA in Adelaide. During his career, Neil has licensed technologies to national and international biotech and pharmaceutical companies and been instrumental in the formation of 17 companies. He has previously held positions as CEO of Vaccine Solutions Pty Ltd (co-owned by CSL Limited and the Queensland Institute of Medical Research), Executive Officer of the CRC for Vaccine Technology (a $42M joint venture) and began his career in banking and finance with Westpac Banking Corporation.

Research Team: 

Julie Dutton BSc (Hons) PhD, Senior Scientist

 Julie Dutton has a first class honours degree in biotechnology from the University of New South Wales and completed her PhD at the Institute for Molecular Bioscience, University of Queensland in 2002. After spending postdoctoral time at UQ and the Johannes Gutenberg University, Mainz, Germany, she was initially employed as a research scientist by Coridon in 2004. Julie is now responsible for the management of Coridon’s scientific program and has a specialist certificate in biomedical research management from the University of Melbourne. 

Yvonne Woo BSc (Hons) PhD, Research Scientist

Yvonne Woo has a first class honours degree and a PhD in immunology from the University of Queensland which focussed on polynucleotide vaccine research.  Apart from experimental work she also assists with project management and compliance with GLP.

Bo Li BSc (Hons) PhD, Research Scientist

Bo Li joined Coridon in 2008 with a PhD in molecular immunology from the Agriculture and Life Sciences Division of Lincoln University, New Zealand.

Yan Xu MD, Research Scientist

Originally trained as a pathologist in China, Yan Xu is one of Coridon’s first employees and has extensive experience in molecular biology techniques, cell culture and immunoassays.